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The prevalence of the most severe forms of HIV-associated neurocognitive disorders
(HAND) is decreasing due to worldwide availability and high efficacy of antiretroviral
treatment (ART). However, several grades of HIV-related cognitive impairment persist
with effective ART and remain a clinical concern for people with HIV (PWH). The
pathogenesis of these cognitive impairments has yet to be fully understood and probably
multifactorial. In PWH with undetectable peripheral HIV-RNA, the presence of viral
escapes in cerebrospinal fluid (CSF) might explain a proportion of cases, but not all.
Many other mechanisms have been hypothesized to be involved in disease progression,
in order to identify possible therapeutic targets. As potential indicators of disease staging
and progression, numerous biomarkers have been used to characterize and implicate
chronic inflammation in the pathogenesis of neuronal injuries, such as certain phenotypes
of activated monocytes/macrophages, in the context of persistent immune activation.
Despite none of them being disease-specific, the correlation of several CSF cellular
biomarkers to HIV-induced neuronal damage has been investigated. Furthermore, recent
studies have been evaluating specific microRNA (miRNA) profiles in the CSF of PWH with
neurocognitive impairment (NCI). The aim of the present study is to review the body of
evidence on different biomarkers use in research and clinical settings, focusing on PWH
on ART with undetectable plasma HIV-RNA.
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INTRODUCTION
Thirty-seven million people are currently living with HIV infection in the world,
according to World Health Organization estimates. A variable proportion of people
with HIV (PWH), suggested up to 60%, might develop some form of HIV-associated
neurocognitive disorder (HAND) in the course of their life (Schouten et al., 2011). HAND
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is categorized as three main conditions based on the severity
of neurocognitive deficits: asymptomatic neurocognitive
impairment (ANI), HIV-associated mild neurocognitive
disorder (MND), and HIV-associated dementia (HAD;
Antinori et al., 2007).
The neurocognitive impairment (NCI) underlying these
conditions has a multifactorial etiopathogenesis, with many
contributing factors. One of the most studied contributing
factors is the uncontrolled replication of HIV in cerebrospinal
fluid (CSF) and brain tissue, causing direct central nervous
system (CNS) damage, further complicating the global picture
of HAND. However, a certain grade of NCI has been found in
PWH on stable antiretroviral treatment (ART) with persistently
undetectable viremia, highlighting ongoing brain volume loss
and white matter injury without association to HIV viral load
(McMurtray et al., 2008; Cardenas et al., 2009; Gongvatana
et al., 2009). These data suggest that the direct role of the
virus alone cannot explain the presence of HAND and that
other factors, such as chronic inflammation, cytokine release
and cellular damage, could all be involved in the pathological
process. Specifically, common autopsy findings in ART-treated
PWH included brain endothelial cell activation and alterations
in neurochemical synaptic transmission with a lymphocyte
infiltrate rather than the monocyte dominant encephalitis
observed in advanced pre-ART HIV disease.
Many factors have been studied so far to determine the
risk of developing HIV-associated NCI, but, until now, a single
marker has not been identified that effectively differentiates
PWH with or without NCI. In PWH with uncontrolled HIV
replication and HAND, therapy is optimized for controlling
viral replication; however, there is no standardized consensus
on therapy targeting HAND for PWH with optimal viral
suppression. The identification of biomarkers with the potential
for predicting or stratifying the risk for NCI could be pivotal
for the early diagnosis of HAND and long-term management of
chronically infected PWH, assessing the efficacy of therapeutic
interventions along time. However, as ART-mediated viral
suppression limits the role of HIV as a mechanism of CNS
injury, potential biomarkers should be investigated between
inflammation-linked or neuronal damage markers that could be
influenced by different individual host characteristics, such as the
genetic likelihood of Alzheimer’s, age, and comorbidities.
In this review article, we analyzed the current body of
evidence concerning biomarkers of NCI in PWH on ART and
with controlled HIV replication, investigating their applicability
in the context of clinical practice. The aim of this review is
to investigate which mechanisms are currently studied and
possibly correlated to NCI, and whether some markers of
neuronal damage or immune activation could be used for
diagnostic purposes or even in the longitudinal follow-up of
ART-treated PWH.
METHODS
This review article is based on the literature analyzing the
markers of NCI in the course of ART-treated HIV infection.
Our review examined all articles published in English and
available on PubMed database until December 16, 2018.
No restriction criteria based on year of publication were
used. Online publications ahead of print were also included.
The PubMed database was screened using the search terms:
{(HIV) [AND NCI] AND marker} NOT review [Publication
Type]. One-hundred and eleven articles published between
August 1996 and December 2018 were initially selected and
screened for eligibility based on title and abstract. With the
aim of eliminating the confounding factor of uncontrolled
CSF viral replication and viral escapes, we excluded studies
performed in ART naïve subject. In vitro studies, post-mortem
studies, and animal studies were also excluded. The remaining
manuscripts were thereafter read in whole, and included
in the review article, if they reported data on at least
one possible marker of NCI, studied in PWH (at least
partly) on ART.
Forty-three articles were excluded because they did not focus
on any biomarker or only concerned viral markers; four because
the studies were performed on animals; two were in vitro studies;
four were post-mortem studies; eight were performed in ART-
naïve PWH or PWH with CSF replicating HIV; four were
reviews (Figure 1).
Forty-six articles were included in the final version of the
review, encompassing 201 distinct hypotheses of correlation
between different biomarkers and NCI.
References cited in the studies were also checked to identify
other relevant articles not found in our initial search.
Technical Limitations
One of the major issues linked to identification of reliable
biomarkers of NCI is the reproducibility of the results.
In fact, the techniques that are used to measure different
biomarkers in different studies are often not fully comparable.
ELISA-based assays, which are commonly used to detect and
dose many biomarkers, have been originally developed to
measure a single analyte and later developed as multiplex
assays, allowing measurement of multiple analytes from a
single sample. However, many different sources and kits from
different manufacturers are now available and they might
provide different results, while the same analyte can be measured
differently in multiplex or single determinations. In addition,
different kits can be designed for different ranges of values with
different software and require different dilutions of the CSF or
plasma, which can confound the data between studies. Also,
the modern omics approach has similar limitations as well. The
results of an omics study can vary with the manufacturer, the
platform, and which version is used, owing to low overlap of
results when the same samples are run on different platforms.
In addition, the omics approach requires correction for multiple
comparisons and discussion of fold change definitions, both of
which are controversial within the fields.
Finally, statisticians often advocate log transformation of
results that may be appropriate for some biomarkers but is
problematic for others. Indeed, log transformation of results may
obscure the marginal values of more labile analytes, whose values
can be at the margin of detection, and leads to publication of
findings driven by a very few positive values.
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FIGURE 1 | Flowchart for study selection.
All those technical issues must be considered in the final
considerations on the significance of the various analytes that
have been studied in CNS.
MARKERS OF NEURONAL DAMAGE AND
ALTERATION OF SIGNALING
Key events that follow invasion of CNS by HIV and contribute
to HAND include direct neuronal apoptosis, dysregulation of
neuronal support cells, and loss of synaptodendritic signaling.
Identifying sensitive CSF biomarkers of HIV-induced neuronal
damage seems essential for HIV/neuroAIDS staging, evaluation
of response to treatment, and clarifying possible mechanisms
of neural damage. We summarized data on available neuronal
damage and alteration of signaling biomarkers, underlying the
main strengths and limitations of the available literature on the
topic (Table 1).
β-Amyloid 42
β-Amyloid 42 (Aβ42) is the major component of brain amyloid
plaques in the course of Alzheimer’s disease, and may activate
mast cells, which could play an important role in Alzheimer’s
disease pathogenesis (Niederhoffer et al., 2009). Patients
without clinical cognitive impairment with Aβ42 pathology
are considered at high risk of preclinical Alzheimer’s disease
(Sperling et al., 2011), cognitive decline (Petersen et al., 2016),
and progression to mild cognitive impairment (Knopman et al.,
2012). Aβ42 levels in CNS have been previously linked to
HIV-RNA load, indicating that HIV replication in the brain
could be an active driver of neuroinflammation and of abnormal
protein clearance (Levine et al., 2016). However, few studies
have focused on Aβ42 levels with successful suppression of HIV
replication. CSF levels of Aβ42 from ART-naïve PWH have been
previously correlated with average white matter hyperintensities
(ρ = 0.319, p = 0.045; Trentalange et al., 2018) that, in turn, have
been associated with cognitive impairment (Mok andKim, 2015).
However, such correlation was not confirmed in ART-treated
PWH (Trentalange et al., 2018), and a study conducted in
94 PWH (72% with HIV-RNA undetectable) did not find a
correlation between CSF Aβ42 levels and abnormalities in the
periventricular white matter (Steinbrink et al., 2013). In the
same study, the CSF Aβ42 was correlated to scores of different
neuropsychological tests, and Aβ42 correlated significantly with
HIV Memorial Sloan–Kettering scale (MSKS) score but not with
HIV dementia scale (HDS) and the Mosaic test (MT) scores
(Steinbrink et al., 2013). Moreover, in ART-treated PWH with
undetectable HIV RNA in their plasma or CSF, CSF Aβ42 levels
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TABLE 1 | Biomarkers of neuronal damage and correlation with neurocognitive impairment (NCI) in people living with HIV.
Biomarker Body fluid Findings Research gaps Reference
β-Amyloid 42
CSF No correlation with white matter hyperintensity in
ART-treated PWH.
Lack of randomized trials; Lack of
longitudinal data; little data in course of ART
Trentalange et al. (2018)
CSF No correlation with abnormalities in the periventricular
white matter.
Steinbrink et al. (2013)
CSF Significant correlation with neuropsychological tests score:
-HIV Memorial Sloan–Kettering scale score
-Not with HIV dementia scale (HDS) and the Mosaic test
(MT) scores
Steinbrink et al. (2013)
CSF NO correlation with GDS. Cysique et al. (2015)
ε4 APOE carriage Association with lower CSF Aβ1-42 concentrations. NO
correlation with NCI.
Association with NCI not proven in HIV Bertram et al. (2008)
ε4 APOE carriage No association with HAND in HIV. Bora et al. (2014)
and Cysique et al. (2015)
Neurofilament proteins
Plasma Higher concentration in worse cognitive performance. No data in correlation with experimental
neuroprotective therapies. Lack of
randomized trials.
Anderson et al. (2018)
CSF Independent biomarker of baseline NCI status. Guha et al. (2019)
CSF Negative association with cognitive performance. Jessen Krut et al. (2014)
and Anderson et al. (2018)
CSF Trend towards higher levels in aviremic PWH with NCI
compared to others.
Edén et al. (2016)
CSF Higher levels in NCI vs. unimpaired PWH. Guha et al. (2019)
CSF High levels in untreated neuroasymptomatic PWH. Jessen Krut et al. (2014)
CSF Predictive of HAD development in
neuroasymptomatic PWH.
Gisslén et al. (2007)
CSF Low levels in ART-treated PWH and in PWH. Jessen Krut et al. (2014)
CSF Levels decline after starting ART. Jessen Krut et al. (2014)
CSF Levels remain stable in course of stable ART. Sacktor et al. (2018)
CSF Similar levels in course of ART in early treated PWH
compared to others.
Oliveira et al. (2017)
CSF Correlation with neopterin levels. Edén et al. (2016)
CSF Direct correlation with C1q in CSF. McGuire et al. (2016)
Calcium binding protein B (S100B)
CSF Higher levels in NCI compared to unimpaired subjects. Little data, lack of longitudinal studies.
Lack of randomized trials.
Yuan et al. (2017) and
Guha et al. (2019)
Tau protein
CSF Higher mean values in PWH with moderate or severe
abnormalities of periventricular white matter.
Little longitudinal data, absence of a defined
cut-off for defining NCI, little use in the follow-up
of PWH on ART. Lack of randomized trials.
Steinbrink et al. (2013)
CSF No correlation with white matter hyperintensities in ART,
weak correlation off ART.
Trentalange et al. (2018)
CSF Significant correlation with neuropsychological test score:
-Memorial Sloan–Kettering scale score
Steinbrink et al. (2013)
-HIV dementia scale score
-Mosaic test score
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TABLE 1 | (Continued)
Biomarker Body fluid Findings Research gaps Reference
CSF Normalization after improvement of neurocognitive function
in a single case report.
Andersson et al. (2006)
CSF No changes in virologically suppressed PWH after switch to
ART regimens with enhanced central nervous system
penetrability.
Tiraboschi et al. (2015)
Phospho-tau CSF Significant correlation with GDS. Cysique et al. (2015)
LIPIDS
Sphingomyelin:ceramide ratio CSF Greater sphingomyelin:ceramide ratios for acyl chain
lengths of C16:0, C18:0, C22:0, and C24:0 were
associated with worse performance on several indices
of memory.
Lack of randomized trials; Lack of
longitudinal data
Mielke et al. (2010)
Sphingomyelin:cholesterol ratios CSF Higher sphingomyelin:cholesterol ratios were significantly
associated with worse performance on the Rey Auditory
Verbal Learning Test trail 5 score (p = 0.018) and
delayed recall.
Mielke et al. (2010)
Extracellular vesicles
CSF Higher in HIV + that in uninfected subjects. Little studied, still no longitudinal data,
absence of solid correlations in
ART-treated PWH. Lack of
randomized trials
Guha et al. (2019)
CSF Higher levels in NCI compared to unimpaired subjects. Guha et al. (2019)
CSF Direct correlation with S100B. Guha et al. (2019)
Wnt pathway
DKK1 Plasma Higher levels in NCI compared to unimpaired subjects,
particularly in PWH taking ART with HIV RNA levels
≤50 copies/mL.
Little studied, still no longitudinal data,
absence of solid correlations in
ART-treated PWH. Lack of randomized
trials.
Yu et al. (2017)
Mitochondrial DNA
CSF Higher levels in NCI compared to unimpaired subjects. Contradictory data, lack of reliable data
in ART-treated PWH; lack of longitudinal
data. Lack of randomized trials.
Pérez-Santiago et al. (2016)
CSF Higher levels in better neurocognitive performance. Pérez-Santiago et al. (2017)
CSF Inverse correlation with NFL levels. Pérez-Santiago et al. (2017)
CSF Association with biomarkers of inflammation (IP-10 in CSF
and MCP-1 in plasma).
Pérez-Santiago et al. (2016)
CSF Higher levels in individuals with detectable CSF HIV RNA
and in the absence of ART.
Mehta et al. (2017)
CSF Higher levels in PWH with mild NCI than in asymptomatic
subjects.
Mehta et al. (2017)
CSF Direct association with IL-6; inverse association with
ceruloplasmin, transferrin, and VEGF.
Mehta et al. (2017)
CSF Direct association with MCP-1 in CSF, TNF-α and IL-8
in plasma.
Pérez-Santiago et al. (2017)
Different mitochondrial haplogroup
carriage
No correlation with IL-6, IL-8, IP-10, and TNF-α in CSF in
African and Hispanic ancestry. Haplogroup H had
significantly lower CSF TNF-α levels in European ancestry
with suppressed plasmatic HIV-RNA viremia.
Samuels et al. (2016)
Abbreviations: ART, antiretroviral treatment; GDS, global deficit score, CSF, cerebrospinal fluid; PWH, people with HIV.
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did not correlate with clinically relevant levels of impairment,
defined in accordance with the Global Deficit Score (GDS)
method, or with past diagnosis of HAND (Cysique et al., 2015).
Also, the ε4 allele of Apolipoprotein E (APOE), an apolipoprotein
thought to be partially responsible for amyloid clearance in the
CNS and a risk factor for late-onset sporadic Alzheimer’s disease
(Bertram et al., 2008), showed no association with HAND in HIV
(Cysique et al., 2015).
Although Aβ42 could probably be used in other settings,
including cognitive impairment in HIV viremic PWH, current
evidences on its use in controlled HIV infection are still limited
and do not offer additional information on cognitive evaluation
and staging in the clinical practice.
Neurofilament Proteins
The light subunit of the neurofilament protein (NFL) is a
major structural element of myelinated axons that is crucial
for maintaining the axonal caliber and facilitating an effective
nerve conduction (Hoffman et al., 1987). Elevated NFL levels
are found in CSF of PWH when this structural component is
released during neuronal and axonal injury, which has been
reported in several neurological disorders including HAND
(Abdulle et al., 2007; Jessen Krut et al., 2014; Peterson et al.,
2014; McGuire et al., 2015; Gisslén et al., 2016; Yilmaz et al.,
2017). In HIV-infected adults, higher plasma NFL concentration
has been significantly associated with worse neuropsychological
performance, after adjustment for possible confounding factors
including age, CD4+ T cell count, and plasma HIV RNA levels
(Anderson et al., 2018). High NFL concentration in CSF was
found to be an independent biomarker of baseline NCI status
in multivariable linear regression models adjusted for age, race,
and plasma viral load (Guha et al., 2019). CSF NFL levels
were also found to correlate with C1q concentrations in CSF
in ART naïve PWH. The complement system (C1q/C3) is a
key mediator of synaptic pruning during normal development
and HIV inappropriately induces C1q and C3 production in
the brain. In a 2016 study of 40 PWH with 58% of PWH
on ART, a nearly significant elevation of CSF C1q expression
was observed in cognitively impaired subjects between 18 and
24 years old compared to cognitively normal subjects, and
within the PWH group, CSF C1q correlated with CSF NFL
levels (McGuire et al., 2016). However, the association between
GDSs and CSF NFL has been observed mostly in individuals
not receiving ART, in which plasma NFLs are higher compared
to PWH receiving ART and usually decline over time after
ART initiation (Andersson et al., 2006; Jessen Krut et al.,
2014; Anderson et al., 2018). A trend towards higher CSF
NFL was also seen in aviremic PWH with NCI compared to
others (Edén et al., 2016) and, in a work including mostly
ART-treated PWH (67 PWH of which 67% aviremic), CSF
NFL levels were higher in PWH with NCI compared to
unimpaired HIV-infected subjects (p < 0.05; Guha et al., 2019).
In the same study, CSF NFL was higher in NCI (p = 0.009)
and HAND (p = 0.007) but not in unimpaired HIV-infected
subjects compared to HIV-uninfected controls (Guha et al.,
2019). In another interesting study, high levels of CSF NFL
were consistently found in HAD subjects and in untreated
asymptomatic PWH, especially those with lower counts of CD4+
T lymphocytes, suggesting a subclinical axonal injury also in
neuroasymptomatic PWH and not on treatment (Jessen Krut
et al., 2014). Importantly, higher CSF NFL levels were found in
neuroasymptomatic PWH compared to CD4-matched controls
in a previous study, in which enrolled PWH were not on
ART or, in some cases, treated with old drug combinations,
which would now be considered suboptimal, and had with
elevated median CSF HIV-RNA levels in both cases and controls
(Gisslén et al., 2007). In a cross-sectional comparison between
ART-treated PWH andHIV-uninfected subjects, only a minority
of subjects [7/85 (8%) and 4/204 (2%), respectively] had high
CSF NFL levels (Jessen Krut et al., 2014), and similar NFL
concentrations were found in PWH under combined ART and in
HIV-negative subjects 3.9 years older (Jessen Krut et al., 2014).
While ART usually reduces CSF NFL concentrations in naïve
subjects (Jessen Krut et al., 2014) in PWH with NCI and on
stable ART, NFL does not seem to change significantly after
24 weeks (Sacktor et al., 2018). Moreover, ART-treated HIV
aviremic subjects had similar CSF NFL concentrations either
if treated early or late (after median 1.8 vs. 17.2 months) for
HIV infection (Oliveira et al., 2017). In conclusion, NFL is a
sensitive biomarker for axonal injury in several neurological
disorders including HAND (Abdulle et al., 2007; Gisslén et al.,
2007, 2016; Yilmaz et al., 2017), and the correlation found
between CSF NFL and neopterin in NCI subjects suggests an
association between NCI, CNS inflammation, and neuronal
damage (Edén et al., 2016). NFL is one of themarkers with amore
consistent correlation with NCI in HIV; however, a longitudinal
evaluation of NFL in ART-treated aviremic PWH seems not to
be informative.
Calcium Binding Protein B
Calcium binding protein B (S100B) is secreted by astrocytes
and oligodendrocytes and can enter the extracellular space or
bloodstream after spilling from injured cells. For this reason,
S100B is considered a peripheral marker of CNS damage and
blood-brain barrier permeability (Blyth et al., 2009; Kazmierski
et al., 2012; Wu et al., 2016). Glial responses in HIV-infected
individuals can be detected by elevation of CSF S100B (Green
et al., 1999; Pemberton and Brew, 2001; Du Pasquier et al.,
2013; Abassi et al., 2017) and its levels have been found to be
higher in the CSF of PWH with NCI compared to unimpaired
HIV-infected subjects (p< 0.05; Guha et al., 2019). In particular,
CSF S100B was higher in NCI (p = 0.023) and HAND (p = 0.002)
but not in unimpaired HIV-infected subjects compared to
uninfected controls in a recent study conducted by Guha et al.
(2019). However, in that study, SB100 was not confirmed as an
independent biomarker of baseline NCI status in multivariable
linear regression models adjusted for age, race, and plasma viral
load (Guha et al., 2019). In another study, significantly higher
levels of S100B were found in CSF of PWH with NCI compared
with PWH without impairment (p = 0.0023); however, the
analysis was unadjusted for possible confounding factors (Yuan
et al., 2017). Definitive studies confirming the role of SB100 in
the evaluation of NCI in the course of aviremic HIV infection are
still lacking.
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Tau Protein
Total-tau and phospho-tau are considered reliable markers of
clinically relevant neurodegeneration. Tau is a protein implicated
in the assembly and stability of microtubules, while phospho-
tau, its hyper-phosphorylated form, is produced in the course
of inflammation and detaches from microtubules, forming
neurofibrillary tangles (Calcagno et al., 2016). In a previous
study performed in PWH (72%with HIV-RNA<200 copies/ml),
higher mean values of total tau have been found in PWH with
moderate or severe abnormalities of periventricular white matter
than in PWH with no or mild abnormalities (p < 0.001 and
p = 0.006, respectively; Steinbrink et al., 2013). The same
findings were also confirmed in PWH with white matter
abnormalities in the area of the basal ganglia, who showed
significantly higher total tau levels (p = 0.0013) compared to
PWH with no, or mild, abnormalities (p = 0.027; Steinbrink
et al., 2013). On the other side, in ART-treated PWH, tau CSF
levels did not correlate with the presence of hyperintensities
in the white matter, which has been in turn associated with
NCI, while a weak correlation was seen in naive PWH
(Trentalange et al., 2018). The correlation among total tau level
in CSF and scores of different neuropsychological tests has
also been evaluated. Total tau correlated with the MSKS score
(r = 0.252; p = 0.018), HDS score (r = 0.268; p = 0.015),
and the MT score (r = 0.229; p = 0.036). Interestingly, none
of those scores correlated with phospho-tau levels (Steinbrink
et al., 2013). On the other hand, greater levels of NCI,
evaluated by the GDS, were associated with higher CSF levels
of phospho-tau (r = 0.10; p = 0.03), but NCI showed only
borderline association at the univariate analysis (p = 0.05) to
CSF total-tau levels, not confirmed at multivariable analysis
(Cysique et al., 2015).
Although the normalization of CSF-tau has been correlated
to improvement of neurocognitive function in a single case of
a person initiating ART (Andersson et al., 2006), no changes in
tau levels were found in studies of switch therapy in virologically
suppressed PWH switching to ART regimens with enhanced
CNS penetrability (Tiraboschi et al., 2015). In summary, tau CNS
levels showed good correlation with both neuroimaging features
and neuropsychological tests evocative of NCI in different
studies. Data are still lacking on the possibility of use of this
marker in the follow up of NCI.
Lipid Biomarkers
During the course of CNS disorders, a disruption in the lipid
metabolism may occur in the CNS, resulting in elevated CSF
levels or brain accumulation of lipid biomarkers. Indeed, levels
of ceramide and sphingomyelin are significantly increased in
brain tissues and CSF of PWH with dementia (Haughey et al.,
2004). This could be due to an induction of the lipid metabolism
caused by the cytokines produced by glial cells. Moreover, an
overproduction of ceramide, resulting from oxidative assault
on lipid membranes in the CNS, can be implicated in brain
accumulation of lipids and increased ceramide in the CSF
of HIV/neuroAIDS subjects (Haughey et al., 2004; Farooqui
et al., 2007). CSF levels of sphingomyelin, ceramide, and sterol
species have been studied and compared with performance
on standard neurological tests in 31 PWH (80% on ART;
Mielke et al., 2010). Greater sphingomyelin/ceramide ratios for
acyl chain lengths of C16:0, C18:0, C22:0, and C24:0 were
associated with poorer performance on memory testing (Mielke
et al., 2010). Moreover, higher sphingomyelin:cholesterol ratios
were found in PWH with lower scores on the Rey Auditory
Verbal Learning Test trail 5 and delayed recall tests (Mielke
et al., 2010). Ceramide C16:0 and ceramide C22:0 levels
were also evaluated in a prospective double-blind trial, in
which PWH were treated with fluconazole, paroxetine or
placebo. The study failed to prove a significant improvement
in plasma and CSF lipid levels. However, in PWH treated
with paroxetine, plasma ceramide C22:0 levels were reduced
more than in those treated with placebo and also a cognitive
improvement was noticed in the same group, although
not consistent across all cognitive domains (Sacktor et al.,
2018). In conclusion, data on lipid biomarkers trend in the
course of suppressive ART are still lacking, and little is
known on the potential use for diagnosis and follow-up of
aviremic PWH.
Extracellular Vesicles
Extracellular vesicles (EVs) are generated from most cell types
and released into blood and CSF to carry and deliver cellular
products to other neighboring or distant cells, including proteins,
lipids, and nucleic acids (Thery et al., 2002; Rashed et al., 2017),
but also, in the course of viral infection, viral proteins (Kadiu
et al., 2012) and pro- or anti-inflammatory factors (Li et al.,
2013). EVs can be classified as exosomes (50–150 nm, originate
from multivesicular bodies) or microvesicles (200 nm to 1 µm,
originate from plasma membrane), depending on their origin
and particle size, and have been studied as possible markers
of many neurologic disorders and neuroinflammatory and
neurodegenerative diseases (Gupta and Pulliam, 2014; Coleman
and Hill, 2015; Madison and Okeoma, 2015; Welton et al., 2017).
Few studies have characterized their role and function in the
course of HIV infection (Sun et al., 2017; Chettimada et al., 2018;
Guha et al., 2019).
In a work including HIV-uninfected and HIV-infected
subjects (67% aviremic), CSF EVs were more abundant in
HIV-infected compared to HIV-uninfected subjects, regardless
of NCI status (p < 0.0001) and were more abundant in NCI
(p = 0.04 and p = 0.011 for EVs and CSF, respectively) or
HAND (p < 0.0001 and p = 0.02 for EVs and CSF, respectively)
compared to unimpaired HIV-infected subjects (Guha et al.,
2019). CSF EV concentrations also showed a positive correlation
with NFL levels, while no correlations were found with S100B
and neopterin (Guha et al., 2019). Although the study of EV
seems promising, evidence to support their use in clinical
practice is still missing.
Wnt Pathway
Wnts are a family of 19 highly conserved, small secreted
glycoproteins that bind to the seven-transmembrane Frizzeled
receptors and its co-receptor, LDL receptor-related proteins
5 and 6, to engage a signaling cascade that culminates
in β-catenin-dependent or -independent signaling. The
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Wnt pathway plays a critical role in cell communication,
differentiation, and survival (Al-Harthi, 2012; Clevers and
Nusse, 2012), and its dysregulation has been linked to
neurodegenerative diseases, including Alzheimer’s disease,
Parkinson’s disease, and amyotrophic lateral sclerosis (Al-
Harthi, 2012; Purro et al., 2014). To date, few data are available
on the signaling and regulation of Wnt pathway in the course
of HIV infection and HAND. Previous studies found that
Wnt/β-catenin was a restriction factor for HIV in astrocytes
(Li et al., 2011; Narasipura et al., 2012; Richards et al., 2015),
and inhibition of Wnt/β-catenin signaling influenced the
glutamate uptake and metabolism in astrocytes (Lutgen et al.,
2016). The Dickkopf-related protein 1 (DKK1) is a secreted
soluble antagonist of the Wnt pathway that induces the rapid
disassembly of synapses in mature neurons, and it mediates
synaptic loss induced by Aβ (Purro et al., 2012). In HIV-infected
subjects, DKK1 levels did differ with NCI (mean 813 pg/ml
vs. 549 pg/ml, p < 0.05), particularly in PWH taking ART
with HIV RNA levels ≤50 c/ml (Yu et al., 2017). Even if
studies are still lacking in HIV, Wnt pathway regulates synaptic
transmission and plasticity, and its study could provide a new
understanding of some neuropathological processes in the
course of HAND.
Mitochondrial DNA
Copy number of mtDNA in the brain and mitochondrial
damage and mtDNA copy number within brain tissue have been
correlated with a variety of neurodegenerative pathologies and
aging. Moreover, considering the similarities of mtDNA with
bacterial genomes, it acts as a ‘‘damage-associated molecular
pattern’’ molecule, triggering toll-like receptor-9 activation
and consequent inflammation. For all these reasons, quantity
of mtDNA in CSF recently emerged as a biomarker of
mitochondrial alteration and has been correlated with brain
inflammation. Pérez-Santiago et al. (2016) first described an
association between mtDNA levels in CSF and neurocognitive
deficits in a group of 28 HIV+ subjects, most of which were
not virologically suppressed neither in plasma nor in CSF
at time of this cross-sectional analysis. Interestingly, a strong
association was demonstrated between mtDNA in CSF and
inflammatory markers, specifically IP-10 in CSF and Monocyte
Chemo-Attractant Protein-1 (MCP-1) in plasma, in individuals
with NCI, thus leading to the hypothesis that PWH with
NCI may have inflammatory responses that differ from PWH
without NCI and may also respond differently to the presence
of mtDNA. A similar analysis was performed in the CHARTER
population to determine the relationship between CSF mtDNA
with CSF inflammatory markers, angiogenesis, iron transport,
and HAND (Mehta et al., 2017). Interestingly, Mehta et al.
(2017) found higher cell-free mtDNA levels in untreated PWH
with detectable CSF HIV RNA. Even if these markers did
not distinguish between PWH with or without NCI, mtDNA
levels were higher in PWH with mild NCI as compared to
asymptomatic subjects. There was also an association between
CSF mtDNA and levels of interleukin-6 (IL-6) within the PWH
group, even after adjustment for HIV RNA and CSF WBC.
Moreover, levels of mtDNA correlated with lower levels of
ceruloplasmin and transferrin, and the angiogenesis marker
VEGF, after adjusting for the presence of HIV RNA and WBCs
in CSF.
In a subsequent wok, Pérez-Santiago et al. (2017) analyzed
the association between CSF, inflammation, and neurocognitive
performance in PWH on long-term ART with persistent viral
suppression in plasma. In this work, cell-free mtDNA in
CSF samples has been inversely associated with peripheral
and CSF inflammation [MCP-1 in CSF, and tumor necrosis
factor-α (TNF-α) and IL-8 in plasma] under virologically
effective ART (also after adjustment for past AIDS diagnosis).
Indeed, contrary to the previous study, in this cohort of virally
suppressed individuals, higher cell-free mtDNA levels within
CSF supernatant were associated with better neurocognitive
performance, as measured by the summary T score. Additionally,
lower mtDNA in the CSF correlated with higher levels of
NFL. Thus, in ART-treated PWH, a disequilibrium in cellular
and mitochondrial function, similar to other neurodegenerative
diseases such as Alzheimer’s disease and Parkinson’s disease,
is recognized, which leads to mtDNA depletion, neuronal
damage, and worse neurocognitive outcomes. Well-defined
longitudinal studies will be needed to clarify the relationship
between free mtDNA and neurocognitive outcomes during
HIV suppression.
Another study approach focused on mtDNA is to define
mitochondrial haplogroups, which have been shown to affect a
range of HIV disease characteristics, including those potentially
related to inflammation. Indeed, in vitro studies have shown
that European mitochondrial haplogroups differ in expression
and methylation of inflammation pathway genes. An analysis
performed by Samuels et al. (2016) on participants from the
CHARTER study who had genetic data and CSF samples showed
no significant associations of any of the four measured CSF
cytokines (IL-6, IL-8, IP-10, and TNF-α) with mitochondrial
haplogroup in participants of African or Hispanic ancestry.
However, in the subgroup of participants of European ancestry
with suppressed plasmatic HIV-RNA viremia, the common
haplogroup H had significantly lower CSF TNF-α levels
(Samuels et al., 2016).
MARKERS OF INFLAMMATION
During ART-mediated viral suppression, the dominant
hypothesis for ongoing brain dysfunction has been linked
to persistent inflammation. Following the introduction of ART, a
sharp decrease of systemic inflammation has been demonstrated
but not with resolution to normal levels. We summarized
increasing evidence of the association between markers of
inflammation and NCI (Table 2).
Monocyte Chemo-Attractant Protein
(MCP-1)
Among the most studied biomarkers of inflammation, MCP-1
is a chemokine produced by a number of cells constitutively
or after oxidative stress (including activated microglia and
astrocytes) and, by regulating migration and infiltration of
monocytes/macrophages, contributes to neuroinflammation and
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TABLE 2 | Biomarkers of inflammation and correlation with NCI in people living with HIV.
Biomarker Body
fluid
Findings Research gaps Reference
MCP-1 CSF Shown to correlate with change in NCI performance in mostly treated
PWH; found to be higher in PWH with NCI compared to non-NCI;
shown to be higher than plasma MCP-1 in PWH with NCI; elevated at
baseline in HIV suppressed individuals with NCI switching therapy.
Lack of randomized trials; Lack of strong longitudinal data;
Lack of studies conducted on large numbers of HIV
suppressed individuals.
Marcotte et al. (2013), Yuan
et al. (2013), Tiraboschi
et al. (2015) and Yuan et al.
(2015)
PLASMA MRI studies show correlation with subcortical injury; shown to be lower
than CSF MCP-1 in PWH with NCI and shown not to correlate with NCI.
Inconclusive data; Lack of randomized trials; Lack of studies
conducted on large numbers of HIV suppressed individuals.
Ragin et al. (2006)
TNF alpha CSF Shown to decrease in 24 weeks in suppressed PWH with NCI after
switch to an ART regimen with high neuropenetration; Levels found to
be slightly lower in PWH having started ART early compared to late ART.
Lack of randomized trials; Limited population numbers. Tiraboschi et al. (2015) and
Oliveira et al. (2017)
IL-6 CSF Levels found to be slightly lower in PWH having started ART early
compared to late ART; showed by one study to correlate to a reduced
likelihood of NCI in PWH, both naïve and on ART.
Inconclusive data; Lack of randomized trials; Lack of
longitudinal studies; Lack of studies conducted on large
numbers of HIV suppressed individuals
Oliveira et al. (2017) and
Kallianpur et al. (2018)
IP-10/CXCL10 CSF Found to be higher in PWH with NCI compared to non-NCI; higher
levels in ART-treated PWH with NCI than in untreated PWH with NCI.
Lack of randomized trials; Lack of longitudinal studies. Yuan et al. (2013) and Yuan
et al. (2015)
PLASMA Found to be higher in PWH with NCI compared to non-NCI; plasma
levels shown to decrease in a study investigating the use of paroxetine
and fluconazole for the treatment of HAND.
Lack of longitudinal studies; viability as a biomarker in
clinical practice has yet to be tested.
Yuan et al. (2015) and
Sacktor et al. (2018)
IL-8 or CXCL-8 CSF Found to be higher in PWH with NCI compared to non-NCI; shown to
be higher than plasma IL-8 in PWH with NCI; CSF levels shown to
increase in a study investigating the use of paroxetine and fluconazole
for the treatment of HAND.
Inconclusive data; Lack of longitudinal studies; Lack of
studies conducted on large numbers of HIV suppressed
individuals
Yuan et al. (2013) and
Sacktor et al. (2018)
IFN-α CSF Found to negatively correlate with several individual and composite
neuropsychological tests, despite lack of correlation with treatment
status.
Lack of randomized trials; Lack of strong longitudinal data;
Lack of studies conducted on large numbers of HIV
suppressed individuals.
Anderson et al. (2017)
IL-16 Serum Found to be associated with slower processing speed. Lack of randomized trials; Lack of strong longitudinal data;
Lack of studies conducted on large numbers of HIV
suppressed individuals.
Okafor et al. (2017)
ICAM5 CSF Found to be higher in PWH with NCI compared to non-NCI, and to
correlate with disease progression in a small number of PWH.
Lack of randomized trials; Lack of strong longitudinal data;
Lack of studies conducted on large numbers of HIV
suppressed individuals.
Yuan et al. (2017)
Plasma Found to be higher in PWH with NCI compared to non-NCI, and to
correlate with disease progression in a small number of subjects.
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injury (Deshmane et al., 2009; Rahimian and He, 2016). A work
from 2006 investigated the relationship between biomarkers
and MRI diffusion tensor imaging measurements of centrum
semiovale, caudate, and putamen, which have been shown to
correlate with cognitive status. In 11 ART-treated HIV-infected
subjects, plasma MCP-1 levels correlated with subcortical injury
(Ragin et al., 2006). A 2013 work aimed at investigating
biomarkers within 98 HIV-infected individuals categorized
according to neurocognitive performance (including ‘‘stably
impaired’’ and ‘‘worsening’’), of which 73% of PWH were
on ART and 54% were virally suppressed. Linear regression
identified that, among markers, only MCP-1 in CSF was
associated with neurocognitive change. Models constructed with
the aim of diagnosis showed that a combination of MCP-1
and TNF-α allowed classifying 100% of the subjects with stable
impairment (Marcotte et al., 2013). In a 2013 preliminary study,
Yuan et al. (2013) measured cytokine levels in the CSF of 107
HIV-infected PWH (43% of whom were on ART) with and
without NCI through quantification bioassays. Cases with NCI
demonstrated significantly higher levels of MCP-1 (along with
IL-8 and IP-10; Yuan et al., 2013). In 2015, Yuan et al. (2015)
compared cytokine levels in paired CSF and plasma samples
from 85 HIV+ individuals (43% of whom were on ART) with
or without NCI. The expression of MCP-1 was significantly
higher in CSF compared to plasma, and more importantly, CSF
MCP-1 was significantly higher among subjects with NCI, while
plasma MCP-1 did not correlate with cognitive impairment
(Yuan et al., 2015). In a 2015 prospective, single-arm pilot
study by Tiraboschi et al. (2015), 12 ART suppressed PWH
with NCI on a regimen including TDF/FTC/EFV were switched
to ABC/3TC/MVC. All participants showed elevated MCP-1
levels (along with neopterin) in CSF at baseline, although no
significant change in MCP-1 levels was detected after week
24 from switch to the regimen with high neuropenetration
(Tiraboschi et al., 2015). In summary, CSF MCP-1 showed
promising correlation to NCI in multiple independent studies
with distinct endpoints and designs. However, most studies
encompassed both untreated and treated PWH (with some of the
latter still being viremic); therefore, the role of CSF MCP-1 as
a viable biomarker for NCI in ART-suppressed PWH is yet to
be assessed.
Tumor Necrosis Factor Alpha (TNF-α)
TNF-α is a proinflammatory cytokine that exerts homeostatic
and pathophysiological roles in the CNS. TNF-α is released
in large amounts by microglia in pathological conditions,
and this production constitutes part of the neuroinflammatory
response and has been associated with a number of neurological
disorders (Olmos and Lladó, 2014). In the aforementioned
2015 prospective, single-arm pilot switch study by Tiraboschi
et al. (2015), a statistically significant reduction in median TNF-α
concentration in CSF was observed after a 24-week switch to
an ART regimen with high neuropenetration; no significant
differences were observed, taking other inflammatory markers
into exam. Of note, median CSF HIV RNA decreased as well
(all participants had suppressed plasma HIV RNA; Tiraboschi
et al., 2015). In a study by Oliveira et al. (2017), paired blood and
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CSF samples were collected from 16 HIV-infected individuals
on suppressive ‘‘early’’ or ‘‘late’’ ART. Median CSF TNF-α
levels were slightly but significantly lower in individuals on
early ART compared to those who had initiated ART later.
No difference was detected among groups for blood TNF-α
(Oliveira et al., 2017).
In conclusion, there is limited but promising evidence in
favor of TNF-α being associated with inflammation due to
uncontrolled/residual viremia. Further studies are warranted.
Interleukin-6
IL-6, a mediator of the acute phase response, can be produced
by astrocytes exposed to HIV (Nitkiewicz et al., 2017). Lower
IL-6 levels in CSF have been observed in individuals who had
started ART early compared to those who had initiated ART
later in a work by Oliveira et al. (2017). No difference was
detected among groups for plasma IL-6 concentration. These
data supported the concept that early ART initiation reduces at
least some inflammation mediators in CSF. A possible effect of
IL-6 on CSF HIV DNA molecular diversity was also explored
but no mediation effect was observed (Oliveira et al., 2017). In
a 2017 work investigating the relationship between CSF levels
of proteins involved in iron transport and/or angiogenesis and
neuropsychiatric impairment in 405 HIV-positive individuals
(73% of subjects on ART, 46% of PWH were virally suppressed),
CSF levels of IL-6 were not found to correlate with HAND.
Of note, CSF IL-6 was shown to correlate to a reduced
likelihood of impairment in 135 patients with mild-moderate
comorbidity (Kallianpur et al., 2018). Despite promising reports,
data concerning a possible role of CSF IL-6 in NCI of PWH
are inconsistent. Further studies are needed to expand the
current knowledge.
Interferon-γ-Inducible Protein (IP-10 or
CXCL10)
IP-10 is a CXC or α-chemokine that acts on its receptor, CXCR3,
to attract activated T cells, NK cells, and blood monocytes.
A potent chemoattractant, it has been proposed to enhance
retroviral infection and mediate neuronal injury. CSF IP-10
levels are known to correlate with CSF HIV-RNA and to
decrease in subjects starting ART (Cinque et al., 2005). In
the aforementioned 2013 preliminary study by Yuan et al.
(2013) on 107 HIV-infected individuals, significantly higher
levels of IP-10 (along with IL-8 and MCP-1) were found in
the CSF of individuals with NCI compared to those without
NCI. Interestingly, IP-10 was the only marker found to be
associated with ART treatment, as CSF IP-10 was found to
be higher in ART-treated PWH with NCI than in untreated
PWH with NCI (Yuan et al., 2013). Again, in 2015, Yuan et al.
(2015) compared cytokine levels in paired CSF and plasma
samples from 85 HIV-infected individuals with or without
NCI. Both CSF and plasma IP-10 were found to correlate with
each other in the PWH cohort (Yuan et al., 2015). In 2018,
Sacktor et al. (2018) published the results of a double-blind,
placebo-controlled trial evaluating paroxetine and fluconazole
for the treatment of HAND. Paroxetine was associated with
improvement in a summary neuropsychological test measure,
and in some—but not all—distinct neuropsychological tests. The
authors investigated changes in biomarkers of cellular stress,
inflammation, and neuronal injury over 24 weeks in response
to treatment. Both paroxetine treatment alone and combined
paroxetine/fluconazole treatment showed a decrease in plasma
IP-10 levels compared to placebo (Sacktor et al., 2018).
In conclusion, a small number of independent studies
with distinct designs and endpoints correlate IP-10 to NCI,
interestingly, both as a plasma and CSFmarker. IP-10 seems to be
a reliable marker for NCI during ART, and correlation to a novel
treatment for HAND has been described. However, viability as a
biomarker in clinical practice has yet to be tested.
Interleukin-8 (IL-8 or CXCL-8)
Produced by macrophages and other cell types, IL-8 is the
primary cytokine involved in neutrophil chemotaxis. In the cited
2013 and 2015 studies by Yuan et al. (2013, 2015). CSF levels
of IL-8 were significantly higher in HIV-infected individuals
with NCI compared to those without NCI. IL-8 levels were
significantly higher in CSF than plasma levels (Yuan et al., 2013,
2015). On the other hand, while the 2018 paroxetine/fluconazole
trial by Sacktor et al. (2018) suggest a beneficial effect of
paroxetine on HAND, both paroxetine treatment alone and
combined paroxetine/fluconazole treatment showed an increase
in CSF IL-8/CXCL-8 levels compared to placebo. Therefore,
despite promising reports, data concerning a possible role of CSF
IL-8 in NCI of ART suppressed PWH is inconsistent.
Interferon Alpha
A renowned antiviral cytokine, interferon α (IFNα) has been
found to be elevated in CSF of individuals with advanced HAD
since the pre-combined ART era.
A 2016 cross-sectional study investigated the association
between IFNα and neurocognitive performance, measured by
an eight-test neuropsychological battery. Of 15 PWH, 60% were
ART-experienced and 20% had undetectable viral load; CSF and
plasma IFNα levels did not differ between treated and untreated
or suppressed and non-suppressed PWH. CSF IFNαwas found to
negatively correlate with three individual tests and the composite
test. Additionally, CSF IFNα correlated strongly with CSF NFL.
Plasma IFNα did not show a significant correlation to cognitive
performance (Anderson et al., 2017). While these results strongly
suggest that CSF IFNα continues to play a role in HAND
pathogenesis during the cART era, they pertain to a single study.
Further works are needed to establish the correlation of IFNα and
NCI in ART-suppressed PWH.
Interleukin-16
IL-16 is a pleiotropic cytokine acting as a chemoattractive and
modulating factor of T cell activation. In a 2017 work aimed at
determining the relationship between body mass index (BMI),
HIV-associated NCI, and the potential mediating effects of
inflammatory cytokines, 90 HIV-infected PWH (86.7% of whom
were virally suppressed) were evaluated. Serum concentrations
of IL-16 were significantly associated with slower processing
speed, independently of BMI (Okafor et al., 2017). None
of the other studies taken into consideration in the present
review showed a significant correlation between IL-16 and NCI.
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Further studies are needed to establish such a correlation in
ART-suppressed PWH.
Intercellular Adhesion Molecule-5
Intercellular adhesion molecule-5 (ICAM5) is an ICAM
expressed on neurons that may inhibit CNS T cell activation.
Elevated levels of ICAM5 have been previously found in patients
with brain injury (Guo et al., 2000; Di Battista et al., 2015).
Only one previous study, according to the selection criteria
chosen for the present review article, addressed changes in
ICAM5 in the HIV-infected population (Yuan et al., 2017). In
that study, higher ICAM5 concentrations were found in PWH
with NCI compared to PWH without impairment. Plasma and
CSF ICAM5 levels showed a significant correlation to each other,
and plasma ICAM5 significantly correlated with CSF S100B
(Yuan et al., 2017). Moreover, high concentrations of plasma
and CSF ICAM5 were found in PWH who developed NCI while
levels did not change in individuals who did not develop any
form of impairment. The change of plasma ICAM5 levels always
corresponded with that in CSF (Yuan et al., 2017). Future studies
will clarify the applicability of these preliminary findings in the
HIV-infected population.
Eotaxin
Eotaxin is a chemokine that acts as a potent eosinophil
chemoattractant and that, according to recent studies, may also
contribute to degenerative processes in the CNS (Huber et al.,
2018). However, only one study, among those selected for the
present review article, addressed the evaluation of this biomarker,
failing to determine any significant findings. In 85 HIV-infected
subjects (43% of whom were on ART), eotaxin levels did not
correlate with the diagnosis of NCI, neither in CSF nor in plasma
(Yuan et al., 2015).
Microbial Translocation Markers
Chronic inflammation after ART introduction has been
associated with microbial translocation with bacterial and fungal
antigens across damaged gastrointestinal tract to drive systemic
and CNS inflammation.
A component of the cell wall of gram-negative bacteria,
lipopolysaccharide (LPS), can reach high plasma levels with
translocation of microbial products across the intestinal mucosa
into the peripheral circulation. LPS is suspected to trigger
monocyte activation and to increase trafficking of infected cells
into the brain (Epple et al., 2009). However, LPS measure is
not easy to perform, as LPS assays are problematic because
of blocking factors in bio-fluids and different types of LPS.
Therefore, LPS cannot be measured in the standard ELISA
format, and results of bioassays provide measures that are
not fully comparable between different sites. In a work by
Vassallo et al. (2013), LPS plasma levels were compared
between 179 PWH with HAND and those with no HAND
(87% of subjects on ART and 67% virally suppressed). A
clear association was found between LPS levels and HAND
in a subset of HCV-positive participants, while the association
was non-significant among the HCV-negative group (LPS had
previously been shown to be elevated in hepatitis C co-infection;
Vassallo et al., 2013). LPS, along with its ligand sCD14, was
also found to be a significant predictor of lower processing
speed in a 2017 randomized clinical trial focused on alcohol
intervention on ART-suppressed heavy drinkers living with HIV
(Monnig et al., 2017).
1,3-β-D-glucan (BDG) is a component of most fungal cell
walls and therefore is thought to be another useful indicator
of gut mucosal barrier impairment. In a 2016 cross-sectional
cohort study, levels of BDG were measured in plasma and
CSF in 21 adults with acute/early HIV infection, started on
ART during the earliest phase of infection with HIV RNA
suppression. Higher plasma BDG levels were significantly
related to higher GDSs, reflecting worse neurocognitive
performance. Interestingly, CSF BDG was only found to be
elevated in two individuals, those with the highest GDSs
(Hoenigl et al., 2016).
In light of the wide body of work supporting the gut–brain
barrier as a novel target in the ART era, LPS is a promising
biomarker. LPS correlates with processing speed at least in a
very specific subset of HIV-positive, ART-suppressed PWH.
However, HCV co-infection represents a significant confounding
factor and further studies on LPS and BDG are warranted in
ART-suppressed PWH.
Growth Factors
Iron Transporters and VEGF
Iron is necessary for mitochondrial function, and its transport
is thought to influence immune activation and angiogenesis
(Cherayil, 2010; Saghiri et al., 2015); iron availability can be
both related to HAND and neurodegenerative diseases (Bhatia
and Chow, 2016; Edén et al., 2016). Altered angiogenesis,
in particular, may lead to disruption of blood-brain barrier
integrity in PWH, with consequent possibility of migration
of activated immune cells into the CNS and development
of inflammation and infection (Nightingale et al., 2014). In
one single study satisfying inclusion criteria for the present
review, VEGF levels and iron transporters (i.e., ceruloplasmin
and aptoglobin) have been studied in relation to NCI in
HIV (Kallianpur et al., 2018). Elevated CSF VEGF levels were
associated with higher GDSs and with NCI, defined by GDS
(Kallianpur et al., 2018). Moreover, aviremic PWH without
neurological comorbidities and with higher ceruloplasmin
levels were more likely to have GDS impairment. The
same results were also found in PWH with higher CSF
haptoglobin levels (Kallianpur et al., 2018). Despite those
preliminary results, the authors of the study highlighted that
the associations they found were not adjusted for multiple
testing and required thus replication and further investigation
(Kallianpur et al., 2018).
Fibroblast Growth Factors
Fibroblast growth factors (FGFs) are implicated in brain
development and in neuroprotective functions. An alteration
of FGF levels in CSF may be linked to neuronal injury and
has been previously described in the course of amyotrophic
lateral sclerosis (Johansson et al., 2003), moyamoya (Yoshimoto
et al., 1997), and Alzheimer’s disease (Mashayekhi et al., 2010).
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FGF levels in CSF have been poorly studied in humans and, in
particular, in the setting of HIV-infected subjects (Bharti et al.,
2016). However, one study performed among 100 PWH (37%
of whom were aviremic) failed to prove a consistent correlation
between FGF-2 levels and cognitive disorders, while finding a
correlation between lower FGF-1 levels and NCI (Bharti et al.,
2016). The body of evidence regarding this marker in the clinical
practice or in studies focused on NCI in the course of HIV is thus
still scarce.
Granulocyte Colony-Stimulating Factor
Granulocyte colony-stimulating factor (G-CSF) is a
hematopoietic growth factor that stimulates proliferation
and differentiation of myeloid cells. However, G-CSF and its
receptor are also expressed by neurons in many brain regions
and recent studies suggested its role as a neurotrophic factor, as
G-CSF has an anti-apoptotic function and stimulates neuronal
differentiation in the brain (Schneider et al., 2005). In the context
of HIV-related NCI, few studies have evaluated G-CSF levels.
In a previous study performed in 85 HIV-infected subjects
(43% of participants were on ART; Yuan et al., 2015), G-CSF
levels did not differ significantly in plasma and CSF, indicating
a possible reliability of blood measurement of this marker
without the need of lumbar puncture. However, G-CSF levels
were significantly higher in PWH with NCI compared to those
who had no impairment, in both CSF (p = 0.0079) and plasma
(p = 0.0191; Yuan et al., 2015). In another study evaluating
a total of 107 CSF samples from PWH, G-CSF levels in the
CSF were not different between ART-treated and untreated
PWH but were higher in PWH with impaired cognition
(Yuan et al., 2013).
Those preliminary results may suggest specificity in G-CSF
levels in identifying PWH with HAND, also in the context of
ART. However, no longitudinal studies are available to date and
the evidence for its use remains very scarce.
IMMUNE ACTIVATION MARKERS
T Cell Activation
Considering the emerging role of inflammation as a contributing
factor in neurological damage in the setting of ART-mediated
virological suppression, well-characterized immune activation
drivers have been explored as potential biomarkers of NCI
during ART. Low CD4/CD8 ratio despite suppressive ART has
been linked to immune activation and used to identify PWH
with accelerated aging at risks of clinical events, including
NCI. By evaluating the association of LPS levels with NCI,
Vassallo et al. (2013) also considered CD4/CD8 ratio, which
was significantly associated with NCI in HCV-negative subjects
in univariate analysis. However, after considering age, proviral
DNA, CD8 T cell count, and CD4/CD8 ratio in a logistic
regression model, only age and proviral HIV-DNA resulted
independently associated to NCI. In a subsequent work, Vassallo
et al. (2013) explored the association between CD4/CD8 ratio,
T-lymphocyte activation, and NCI in a large cohort (200 PWH)
of virologically suppressed individuals on ART. They found that
in ART-treated PWH on stable therapy for at least 3 years
with virological suppression, a CD4/CD8 <1 resulted in an
independent risk factor for symptomatic HAND (Vassallo
et al., 2013). Moreover, a significant correlation between
CD4/CD8 ratio and T-cell activation (measured by the number of
CD4+CD38+HLADR+ T lymphocytes) was found, contributing
to the evidence that CD4/CD8 ratio can be considered as a
marker of chronic immune activation. A similar analysis was
performed in MSM (men who have sex with men) Neurocog
Study, in which 200 HIV-infected MSM PWH were screened
for NCI and, after excluding people suffering from anxiety,
depression or previous diagnosis of mood disorders, 20 were
identified as potentially having NCI (Rawson et al., 2015).
In this study, no significant difference in current, nadir or
peak CD4 and CD8 counts, CD4/CD8 ratios, CD4/CD8 ratio
inversion (<1), plasma viral load detectability, and peak plasma
viral load were identified between subjects with NCI and the
control group. Thus, until now, no definitive demonstration has
been reached to define any significant benefit in monitoring
CD8 T cells or CD4/CD8 T cell ratio inversion as an indicator
of NCI.
Recently, Merlini and coauthors evaluated the effects of
12 months of virally suppressive ART on the peripheral and CSF
pro-inflammatory milieu (Merlini et al., 2018). As expected, they
found a decline in both plasma and CSF viral replication after
12 months of ART, and a simultaneous reduction in peripheral
and CSF immune activation, measured by CD38+CD8+ cells,
sCD14, IL-6, MCP-1, and IP-10. Interestingly, subjects with
high pre-ART CSF/plasma HIV-RNA ratio maintained a
skewed T cell homeostasis toward more effector/exhausted
phenotype after ART introduction. In contrast, HIV people
with low CSF/plasma HIV-RNA at baseline displayed a
trend toward recovered peripheral CD4+ and CD8+ T
cells phenotypes, thus suggesting that a lower pre-ART
CSF viral burden and a subsequent viral suppression can
prevent CNS invasion by HIV and consequent detrimental
immune activation.
Monocyte/Macrophage Activation
Considering the role of the monocyte–macrophage lineage
in the HIV-associated CNS disease, activation specifically
involving these cells has been studied as a potential marker of
neurocognitive damage during ART-mediated viral suppression.
Neopterin
Neopterin is a metabolite of guanosine triphosphate catabolism,
and its increase in CSF is considered a marker of macrophage
and microglial activation (Rahimian and He, 2016) and an
independent predictor of CSF NFL levels (Jessen Krut et al.,
2014). CSF neopterin levels are usually high in PWH who
do not receive ART (Fuchs et al., 1989) and may decrease
after ART initiation, possibly in parallel with improvement
of neurocognitive function in the course of ART (Andersson
et al., 2006). However, in certain individuals, some levels
of immune activation may persist in the CNS also after
the achievement of undetectable HIV-RNA levels, and the
concentrations of CSF neopterin remain elevated for a long
time also after having started ART (Edén et al., 2007; Yilmaz
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et al., 2013). In ART-treated PWH, neopterin level correlates
with white matter hyperintensities that are in turn associated
with neurological complications, including cognitive impairment
(ρ = 0.321, p = 0.064; Trentalange et al., 2018). However,
the direct correlation between neopterin levels and NCI in
HIV-infected aviremic subjects is not univocal. In a recent work
including 112 subjects (67% aviremic), neopterin was not an
independent biomarker of baseline NCI status in multivariable
linear regression models, adjusted for age, race, and plasma
viral load (Guha et al., 2019). These findings corroborated
the results of two previous studies, in which no correlation
was found between CSF neopterin and GDS (Bharti et al.,
2016; Pérez-Santiago et al., 2016). Both studies were limited
by a relatively small sample size, and a large part of the
study population had detectable HIV viremia. However, CSF
neopterin levels were not found to be significantly different
between neurocognitively normal, ANI, and MND PWH in
another study conducted on a population of aviremic PWH
(n = 37; Burdo et al., 2013). On the other hand, in that same
study, higher levels of neopterin were found in PWH who were
more impaired by GDS criteria than in those without cognitive
impairment, and higher levels were also found in people with
an executive domain impairment compared to others (Burdo
et al., 2013). Similar results were reported in another recent
study performed in aviremic PWH, in which CSF neopterin
was higher in aviremic PWH with NCI compared to others
(p = 0.04; Edén et al., 2016).
However, a study performed on 99 aviremic PWH followed
up longitudinally did not prove a difference in the proportion
of abnormal neopterin levels between PWH with or without
a decline in the neurocognitive function (Edén et al., 2016).
In another longitudinal evaluation, after persistent undetectable
viremia, CSF neopterin at second visit was significantly higher
than at first visit after a median of 16 months, despite ART
use and long-term viral suppression (p = 0.05, paired t-test;
Burdo et al., 2013). Furthermore, no changes in neopterin levels
were found in a longitudinal study evaluating ART switch to
regimens with enhanced CNS penetrability (Tiraboschi et al.,
2015), neither in PWH initiating paroxetine in a double-blind
trial, in which paroxetin use correlated with improvement in
neurocognitive function (Sacktor et al., 2018). The correlation of
CSF neopterin levels and scores of different neuropsychological
tests has also been evaluated in aviremic PWH. Higher levels of
neopterin were correlated with poorer results on forward Corsi
Block Tapping Test (r = −0.474; p = 0.004), backward Corsi
Block Tapping Test (r = −0.468; p = 0.005), forward Digit
test (r = -0.480; p = 0.004), Verbal Fluency test (r = −0.361;
p = 0.033), Raven’s Standard Progressive Matrices test
(r = −0.308; p = 0.071), the time estimation during the Test
of Weights and Measures Estimation (r = −0.295; p = 0.085)
and the Test of Weights and Measures total score (r = −0.294;
p = 0.087; Ceccarelli et al., 2017). In conclusion, while neopterin
CSF levels might be considered a reliable marker of macrophage
and microglial activation and a predictor of worse performance
in some cognitive domains, its use in the longitudinal follow-up
of aviremic PWH is not sustained by current evidence. Further
studies, possibly combining the evaluation of many biomarkers
of immune activation and neuronal injury, could help improve
its utility in the definition and diagnosis of neurologic disorders
in the course of HIV.
Soluble CD14
Soluble CD14 (sCD14) is the soluble form of the monocyte
LPS receptor, cleaved and released from the membrane after
monocyte activation (McGuire et al., 2015). In a 2011 study by
Lyons et al. (2011), relationships between plasma sCD14, CCL2,
and LPS levels and neurocognitive test scores were investigated
in 97 HIV-infected subjects. Plasma sCD14 levels were higher
in subjects with test scores indicating global impairment,
particularly in attention and learning domains, regardless of
HAND diagnosis. The authors suggest such results imply the
involvement of cortical and limbic pathways by inflammatory
processes in the cART era. Of note, individuals in the study
population were on ART in 74% cases, of which 39% had
undetectable plasma HIV RNA (Lyons et al., 2011). In 2017,
a secondary analysis on a randomized clinical trial focused on
alcohol intervention was published by Monnig et al. (2017)
investigating the relationship between the gut–brain axis, HIV
infection, and alcohol consumption. Blood samples and cognitive
scores were obtained at baseline and 3-month follow-up of the
trial from 21 HIV-positive, ART-suppressed, heavy drinkers.
sCD14 (along with LPS) was found to be a significant
predictor of lower processing speed (Monnig et al., 2017).
In a 2018 work evaluating MRI white matter hyperintensity
(WMH) in naive compared to treated HIV-infected individuals
(n = 107), plasma sCD14 levels were weakly associated with
WMH score; however, no consistent associations between
plasma biomarkers, CSF biomarkers, and WMH scores were
found. Of note, sCD14 levels were lower in treated PWH
compared to naive individuals (Trentalange et al., 2018). In
conclusion, there is evidence that plasma sCD14, a well-studied
monocyte activation marker, correlates with processing speed
at least in a very specific subset of ART-suppressed PWH.
Promising data suggest a correlation with global impairment and
MRI signal, but new studies are warranted involving aviremic
PWH exclusively.
Soluble CD163
One of the most promising pathways, CD163, is released from
macrophage surface and shed as soluble CD163 (sCD163)
following activation and differentiation of monocyte and
macrophages. It has been hypothesized that virologically
suppressed PWHwould show persistent activation ofmonocytes,
which could be assessed by measuring sCD163 in blood, which
would correlate with HAND. A 2013 longitudinal study by
Burdo et al. (2013) on 34 ART-suppressed individuals showed
that PWH with NCI by GDS metrics had higher plasma
sCD163 than those who were not impaired. Interestingly, CSF
sCD163 did not correlate to GDS. Such results were discussed
to be consistent with persistent monocyte/macrophage activation
in neurophysiologically impaired HIV-infected individuals
despite virally suppressive ART (Burdo et al., 2013). In a
2015 study, the relationship between cell-free mtDNA in CSF
and neurocognitive performance during HIV infection, CSF
sCD163 was the sole soluble inflammatory biomarker whose
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levels trended toward being higher in PWH with NCI compared
to those without NCI. Of note, only 45% PWH were on ART
(33% with viremia below the threshold of detectability; Pérez-
Santiago et al., 2016). Bryant et al. (2017) conducted a study in
2017 evaluating sCD163 levels in ante mortem plasma (n = 54)
and CSF (n = 32) samples from 74 HIV-infected participants
who donated their brains to research at autopsy. Higher plasma
sCD163 was found to be associated with greater synaptodendritic
damage and microglial activation in cortical and subcortical
brain regions at autopsy. Despite this, interestingly, plasma
sCD163 was showed not to have any correlation to HAND
diagnosis and neuropsychological test performance. On another
note, CSF sCD163 was not associated with any histological
feature (Bryant et al., 2017). In conclusion, a group of diverse
studies suggest that plasma sCD163 correlates with NCI in
virologically suppressed ART-treated individuals and to neural
damage in PWH, regardless of symptoms, and CSF sCD163 tends
to be higher in PWH with NCI. Such results, albeit partly
inconsistent, are promising and warrant further investigation.
Monocyte Phenotypes
A number of studies focused on different monocyte phenotypes
in blood that may drive HAND neuropathogenesis. Specifically,
HIV infection has been correlated to an expansion of CD14+
monocytes expressing CD16+: CD14++CD16+ (intermediate)
and CD14+CD16++ (nonclassic) monocytes, reaching variable
levels depending on the stage of disease and use of ART.
As CD16+ monocytes express higher levels of cell migration
markers (i.e., CXCR5, CXCR1, and integrin CD11b) and
transmigrate across the blood-brain barrier more efficiently
than CD16− cells, it has been suggested that such cells
can be involved HAND pathogenesis. In a recent study, a
trend toward lower proportions of circulating intermediate
monocytes in PWH who displayed a significant decline in
memory performance during ART-mediated viral suppression
was shown, suggesting an increase of transmigration of this cell
subset in the CNS (Fabbiani et al., 2017). In addition, PWH
with a significant decline in memory performance over time had
lower expression of surface CD163 on the subset of intermediate
monocytes/macrophages, corresponding to a higher release of
sCD163 (Fabbiani et al., 2017).
As activated macrophages secrete soluble factors potentially
toxic to neurons, some authors focused on the measurement of
cytokines, proteases, and other factors produced by these cells
after stimulation. Cathepsin B, a factor secreted by macrophages,
has been described as a protease linked to neuronal apoptosis and
inflammation. Moreover, cathepsin B, together with cystatins B
and C, has been shown to be overexpressed by HIV-infected
monocyte-derived macrophages (MDMs). In a study conducted
on a population of mostly ART-treated (>80%) HIV women,
Cantres-Rosario et al. (2013) showed a significantly higher
proportion of intracellular cathepsin-B and cystatin B in CD14+
cells of HIV+ subjects with HAD compared to subjects without
neurological impairment. Additional analyses on the same study
evaluating cathepsin B levels and activity together with cystatin
C levels on monocytes did not reveal any difference between
HAD subjects and controls. Taken together, these studies suggest
a role for monocyte subpopulation as candidate biomarkers and
suggest new opportunities to target viral reservoirs within the
CNS, thus reducing neuroinflammation, neuronal damage, and
cognitive impairment.
OMICS APPROACH TO NCI MARKERS
RESEARCH
Genomics
Considering that not all HIV-infected subjects develop some
form of neurocognitive disorder, the study of genetic factors
that could possibly predispose to neurologic disease has attracted
increasing interest and some studies aimed at characterizing
the genetic profile of HIV-infected individuals at increased
risk for HAND. CCL3L1, a potent ligand for CCR5 receptor
and chemoattractant for macrophages, displays significant copy
number differences among different ethnic groups. In this
regard, Gonzalez et al. (2005) reported that the risk of AIDS
events, including NCI, was higher when CCL3L1 chemokine
gene copy was lower than the average of the same ethnic
group, together with CCR5 detrimental alleles. A subsequent
study performed by Brown et al. (2012) confirmed previous
data about differences in CCL3L1 median copy number between
various ethnicities; however, CCL3L1 copy number was similar
in patients infected with HIV who had any form of HAND and in
those who did not. Levine et al. (2016) in a very comprehensive
study quantified multiple histopathological markers, genotyped
genes associated with risk of NCI, and measured HIV-RNA
in brain tissues. In this multilevel analysis, they found that
MAP2 and SYP, which are two markers of synaptodendritic
integrity, showed the more robust correlation with HAND
with global pre-mortem cognitive function and with HIV-RNA
viral load in the same regions. Moreover, a concomitant
increase of Aβ and Iba-1 (ionized calcium-binding adaptor
molecule-1) was evidenced as HIV-RNA increased, suggesting
dysfunctional protein clearance and neuroinflammation. Genetic
markers that predicted histopathology included MIP1-α and
DRD3 genotype that are predictors of Iba-1 immunoreactivity,
IL1-α genotype that predicted GFAP (glial fibrillary acidic
protein) immunoreactivity, and ApoE genotype that predicted
Aβ immunoreactivity. These data seem to support a pathogenetic
model in which CNS HIV replication represents one of the
main drivers for neuroinflammation and abnormal clearance.
As a consequence, synaptodendritic degeneration occurs, leading
to NCI of proteins. Genetic polymorphisms in genes encoding
cytokines and chemokines and neuronal protein clearance
pathways could influence histopathological degeneration.
Transcriptomics
Levine et al. (2013) in the last years applied a new research
approach by examining the comprehensive gene expression of
blood monocytes, with the aim of identifying the transcriptional
changes possibly linked to HIV-associated NCI. Specifically
aiming to describe peripheral molecular genetic mechanisms
favoring the development of HAND, they firstly described that
dysregulation of Kelch-like ECH-associated protein-1 (KEAP1),
hypoxia upregulated-1, and IL-6 receptor, implicating oxidative
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stress, constituted a possible underlying pathogenic process.
In a recent work published in 2018 (Quach et al., 2018),
they further expanded these observations by validating the
original findings in an independent sample of participants from
the Multicenter AIDS Cohort Study (MACS) and determined
whether gene expression changes evaluated at baseline could
predict NCI at 2-years of follow-up. Contrary to what is expected,
results from this new study did not replicate observation
from their previous analysis and gene expression profiles
at baseline were not predictive of neurocognitive decline in
the following 2 years. Considering the inconsistency of these
two observations, we have no evidence that gene expression
profiles of monocytes can constitute a reliable biomarker
of HAND.
Proteomics and Metabolomics
Multiplex mass spectrometry-based approaches allow the
analysis of multiple samples in a single experiment. MS
techniques make it possible to study a multitude of proteins
and their differential level of expression at the same time
in the course of CNS diseases. PWH with HAND have
been compared to PWH without HAND and to uninfected
controls (Bora et al., 2014) using proteomics approach,
studying 193 different proteins. A cut-off of 1.5-fold was
used to define protein upregulation. Five proteins among
those previously described as HIV-interacting proteins were
found to be upregulated in PWH with HAND: endoplasmin,
mitochondrial damage mediator-BH3-interacting domain death
agonist, orosomucoid, APOE, and metalloproteinase inhibitor
2. On the contrary, using a cut-off of 0.6-fold to measure
downregulation, peroxiredoxin-2 isoform, a ruvB-like 2 protein,
had lower expression in HAND (Bora et al., 2014). Untargeted
CSFmetabolite profiling was also used with the aim of identifying
an altered metabolic path that can be linked to HAND.
Neurotransmitter production, mitochondrial function, oxidative
stress, andmetabolic waste were studied (Cassol et al., 2014). CSF
metabolites of ART-treated PWH with HAND were compared
to unimpaired patients with similar demographic characteristics.
Despite the metabolite expression being similar in the two
groups after multiple testing correction, recursive support vector
machine (SVM) classificationmodels identified eight metabolites
(including glutamate, myo-inositol, beta-hydroxybutyric acid,
1,2-propanediol) capable of discriminating the presence of
HAND with an accuracy that exceeded 85%. Glutamate and
N-acetylaspartate of myo-inositol and ketone bodies (beta-
hydroxybutyric acid, 1,2-propanediol) showed increased levels
in HAND and also had a correlation with lower scores
in neurocognitive tests, plasmatic markers of inflammation,
and intrathecal interferon responses (Cassol et al., 2014).
The profile of the biomarkers that have been delineated in
this study highlights how, also in the absence of detectable
HIV-RNA, an abnormal synthesis of neurotransmitters, glial
activation, altered mitochondrial function, and accumulation
of metabolic waste products may all be driving forces for the
development of HAND. While further validation is needed,
proteomics and metabolomics studies show the potential of
identifying new biomarkers and cluster of biomarker expression
in different neurocognitive disorders that could potentially give
new evidence about this new promising approach.
MicroRNA
MicroRNAs (miRNAs) have been abundantly demonstrated in
the brain, where they regulate synaptic plasticity and brain
development, implying that miRNA dysregulation may parallel
neurocognitive dysfunction. First, a study on HIV subjects
compared miRNA profiling on tissue from frontal cortex and
CSF in PWHwith or without HAND to healthy controls (Pacifici
et al., 2013). In this article, the authors showed a different
expression of 66 miRNA in CSF, of which 35 were also found in
the frontal cortex. Specifically, they identified four miRNA with
identical expression in tissue in CSF and one miRNA 20-fold
higher expressed in CSF compared to brain tissue. Analysis of
significantly altered miRNA showed their role in remodeling
of cytoskeleton, cellular adhesion, expression of chemokine,
neurogenesis, axonal guidance, notch signaling, synaptogenesis,
and nerve impulses.
In a pilot study by Kadri et al. (2015), a plasma miRNA
signature was associated with NCI in a cohort of PWH cared
at LSU Health Sciences Center (LSUHSC) HIV Outpatient
Clinic (HOP). As they did not consider alcohol consumption
in this study, they later analyzed the miRNA profiling in the
setting of alcohol use disorders in newly recruited PLWHA at
the LSUHSC HOP clinic (Wyczechowska et al., 2017). They
found that alcohol use disorders can represent a confounding
factor for miRNA profile linked to HAND. Moreover, they
confirmed their previous analysis using plasma samples from the
CHARTER study and, also considering differences in the two,
they validated a miRNA profile including 15 miRNA pairs that
differentiate cognitively impaired PWH in both sites, LSUHSC
and CHARTER.
Evidence from these studies, despite the many variables
affecting circulating miRNA and thus encoding as potential
confounders, could serve as a rationale for the development of
novel tools for diagnosis and monitoring of HAND.
CONCLUSIONS
In themodern ART era, considering the benefit in life expectancy
of PWH, it is crucial to reassess the pathogenesis of HAND
and the influence of age, ART, and comorbidities. Several
studies have been performed to identify quantitative CSF/blood
biomarkers for HAND; however, many gaps remain to be
addressed: (i) most studies are cross-sectional, thus lacking to
demonstrate a predictive role for the biomarkers associated
with NCI; (ii) NCI classification is often analyzed as classical
categories (ANI, MND, and HAD), thus losing the possibility
to define markers associated with the evolution of individual
cognitive performance; (iii) a minority of works evaluated the
effect of optimized ART on possible CSF/blood biomarkers
associated to different neurocognitive behavior, thus lacking
information on the potential use of these markers to guide ART
use and selection.
Use of an approach aimed to explore multiple biomarkers
could help clarify the most critical gaps in current HIV
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research, and it is likely that omics approaches (transcriptomics,
proteomics, and metabolics) will accelerate HAND biomarker
discovery and validation with a possible impact on the
development of adjunctive treatment and monitoring of
CNS disease.
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